6 results
Whether disrupting reconsolidation by a noradrenergic beta-blocker provides long-term relief from nicotine-addiction.
The primary objective of this study is to characterize the pharmacokinetic (PK) profile of asciminib in pediatric patients, with the goal of identifying the pediatric formulation dose (fed) leading to asciminib exposure comparable to 40 mg BID in…
Here, we aim to test whether disrupting reconsolidation by a noradrenergic *-blocker provides long-term relief of panic symptoms in burned-out employees.
Whether disrupting reconsolidation by a noradrenergic β-blocker provides long-term relief of PTSD symptoms in traumatized healthcare workers.
Primary:To assess the tolerability of asciminib versus nilotinib with respect to the time to discontinuation of study treatment due to adverse event.Secondary:• Efficacy of asciminib versus nilotinib in terms of discontinuation due to lack of…
Whether disrupting reconsolidation by a noradrenergic *-blocker provides long-term relief of PTSD symptoms in combat veterans.